Lowest-Rated StocksLowest-RatedNASDAQ:FULC Fulcrum Therapeutics (FULC) Stock Price, News & Analysis $3.82 -0.03 (-0.78%) Closing price 04:00 PM EasternExtended Trading$3.82 0.00 (-0.13%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Fulcrum Therapeutics Stock (NASDAQ:FULC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Fulcrum Therapeutics alerts:Sign Up Key Stats Today's Range$3.80▼$3.8550-Day Range$3.50▼$3.9152-Week Range$2.83▼$15.74Volume1.11 million shsAverage Volume1.65 million shsMarket Capitalization$291.47 millionP/E RatioN/ADividend YieldN/APrice Target$8.20Consensus RatingReduce Company Overview Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms. Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression. The company’s pipeline combines discovery-stage projects with clinical-stage assets, reflecting its commitment to translating foundational science into potential therapies for underserved genetic disorders. Founded in 2015 and headquartered in Cambridge, Massachusetts, Fulcrum maintains research and development facilities in both Cambridge and the San Francisco Bay Area. The company is led by President and Chief Executive Officer Steven L. Holtzman, whose leadership team includes professionals with extensive experience in drug development, regulatory affairs and commercial strategy. Fulcrum collaborates with patient advocacy groups, academic institutions and contract research organizations to advance its programs and broaden access to promising new treatments. Fulcrum Therapeutics serves a global patient population by pursuing therapies for rare and serious genetic diseases with significant unmet medical need. The company’s integrated approach—combining a deep understanding of epigenetic mechanisms with state-of-the-art drug discovery capabilities—positions it to address complex disorders for which conventional therapeutic strategies have been largely ineffective.AI Generated. May Contain Errors. Read More Fulcrum Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreFULC MarketRank™: Fulcrum Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 563rd out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingReduce Consensus RatingFulcrum Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, 1 buy rating, 7 hold ratings, and 4 sell ratings.Upside PotentialFulcrum Therapeutics has a consensus price target of $8.20, representing about 114.7% upside from its current price of $3.82.Amount of Analyst CoverageFulcrum Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Fulcrum Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Fulcrum Therapeutics are expected to grow in the coming year, from ($0.69) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulcrum Therapeutics is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulcrum Therapeutics is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulcrum Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Fulcrum Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.41% of the float of Fulcrum Therapeutics has been sold short.Short Interest Ratio / Days to CoverFulcrum Therapeutics has a short interest ratio ("days to cover") of 5.01.Change versus previous monthShort interest in Fulcrum Therapeutics has recently increased by 0.37%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFulcrum Therapeutics does not currently pay a dividend.Dividend GrowthFulcrum Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.56 News SentimentFulcrum Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Fulcrum Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for FULC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Fulcrum Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Fulcrum Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $65,700.00 in company stock.Percentage Held by Insiders7.30% of the stock of Fulcrum Therapeutics is held by insiders.Percentage Held by Institutions89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fulcrum Therapeutics' insider trading history. Receive FULC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FULC Stock News HeadlinesFulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of "Reduce" by AnalystsSeptember 6 at 3:30 AM | americanbankingnews.comFULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its ShareholdersSeptember 5 at 10:59 AM | businesswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 8 at 1:00 AM | Porter & Company (Ad)Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) on Behalf of Shareholders for Possible Securities Law ViolationsSeptember 4, 2026 | markets.businessinsider.comKaplan Fox Advises Investors of Fulcrum Therapeutics, Inc. (FULC) to Contact the Firm Regarding a Securities InvestigationSeptember 2, 2026 | markets.businessinsider.comKaplan Fox Announces an Investigation into Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Possible Securities Law ViolationsSeptember 2, 2026 | theglobeandmail.comKaplan Fox is Investigating Possible Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)August 27, 2026 | theglobeandmail.comKaplan Fox Announces an Investigation of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) on Behalf of InvestorsAugust 26, 2026 | theglobeandmail.comSee More Headlines FULC Stock Analysis - Frequently Asked Questions How have FULC shares performed this year? Fulcrum Therapeutics' stock was trading at $11.31 at the beginning of the year. Since then, FULC shares have decreased by 66.2% and is now trading at $3.82. How were Fulcrum Therapeutics' earnings last quarter? Fulcrum Therapeutics, Inc. (NASDAQ:FULC) released its quarterly earnings data on Thursday, July, 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.10. When did Fulcrum Therapeutics IPO? Fulcrum Therapeutics (FULC) raised $76 million in an initial public offering on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO. Who are Fulcrum Therapeutics' major shareholders? Top institutional investors of Fulcrum Therapeutics include BlackRock Inc. (11.57%), Nantahala Capital Management LLC (7.18%), Montanova Capital LLC (4.82%) and ADAR1 Capital Management LLC (2.05%). Insiders that own company stock include Ra Capital Management, LP, Robert J Gould, Greg Tourangeau and Alan Ezekowitz. View institutional ownership trends. How do I buy shares of Fulcrum Therapeutics? Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fulcrum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fulcrum Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings7/30/2026Today9/08/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 FULC's financial health is in the Red zone, according to TradeSmith. FULC has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:FULC CIK1680581 Webwww.fulcrumtx.com Phone(617) 651-8851FaxN/AEmployees100Year Founded2016Price Target and Rating Average Price Target for Fulcrum Therapeutics$8.20 High Price Target$24.00 Low Price Target$3.00 Potential Upside/Downside+114.7%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-25.38% Return on Assets-24.15% Debt Debt-to-Equity RatioN/A Current Ratio31.35 Quick Ratio31.35 Sales & Book Value Annual Sales$80 million Price / Sales3.64 Cash FlowN/A Price / Cash FlowN/A Book Value$6.45 per share Price / Book0.59Miscellaneous Outstanding Shares76,300,000Free Float70,727,000Market Cap$291.47 million OptionableOptionable Beta2.59 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:FULC) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our PartnersThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredModerna’s 177% Surge Puts Cancer Biotech Back in FocusModerna shares surged 177% in a single trading session on August 19, adding about $45 billion in market value ...The Tomorrow Investor | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredMusk just exposed the crack in his empireSpaceX's IPO raised approximately $85.7 billion in gross proceeds. Days later, the company revealed its combin...The Oxford Club | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
